ATE426610T1 - Nandrolon-17ss-carbonate - Google Patents

Nandrolon-17ss-carbonate

Info

Publication number
ATE426610T1
ATE426610T1 AT06719336T AT06719336T ATE426610T1 AT E426610 T1 ATE426610 T1 AT E426610T1 AT 06719336 T AT06719336 T AT 06719336T AT 06719336 T AT06719336 T AT 06719336T AT E426610 T1 ATE426610 T1 AT E426610T1
Authority
AT
Austria
Prior art keywords
alkyl
compounds
disclosed
bond
cycloalkyl
Prior art date
Application number
AT06719336T
Other languages
English (en)
Inventor
Richard Blye
Hyun Kim
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE426610T1 publication Critical patent/ATE426610T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Steroid Compounds (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06719336T 2005-02-04 2006-01-24 Nandrolon-17ss-carbonate ATE426610T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65037605P 2005-02-04 2005-02-04

Publications (1)

Publication Number Publication Date
ATE426610T1 true ATE426610T1 (de) 2009-04-15

Family

ID=36283873

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06719336T ATE426610T1 (de) 2005-02-04 2006-01-24 Nandrolon-17ss-carbonate

Country Status (8)

Country Link
US (1) US7820642B2 (de)
EP (1) EP1846434B1 (de)
JP (1) JP5227593B2 (de)
AT (1) ATE426610T1 (de)
AU (1) AU2006211907B2 (de)
CA (1) CA2596884C (de)
DE (1) DE602006005901D1 (de)
WO (1) WO2006083618A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109575098B (zh) * 2019-01-18 2021-01-01 湖南成大生物科技有限公司 诺孕美特的合成方法
CN110128529B (zh) * 2019-04-11 2023-07-07 中国农业科学院兰州畜牧与兽药研究所 一种去甲睾酮人工抗原的合成方法
US20230227492A1 (en) * 2020-06-11 2023-07-20 The Usa As Represented By The Secretary, Department Of Health And Human Services Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3056727A (en) * 1960-10-27 1962-10-02 Roussel Uclaf Cyclohexylcarbonates of steroids
FR1215M (fr) * 1961-03-28 1962-04-02 Roussel Uclaf S A Soc Nouveau médicament, notamment pour le traitement des troubles dus a une hyperestrogénie ou a une hypoandrogénie.
FR6576M (de) * 1965-10-11 1968-12-30
FR5913M (de) * 1965-12-02 1968-04-01
US3629244A (en) * 1966-01-21 1971-12-21 Roussel Uclaf 17beta-ethers of delta 4 9 11-gonatrienes and compositions containing them
US3523126A (en) * 1967-12-13 1970-08-04 Du Pont Testosterone and 19-nortestosterone(4'-methylbicyclo(2,2,2)octane - 1' - methyl)carbonate and selected derivatives
GB1291293A (en) * 1970-05-29 1972-10-04 Du Pont Steroid carbonates and their preparation
GB1355663A (en) * 1970-06-17 1974-06-05 Theramex 19-nortestosterone 17- -p-substituted phenoxy-acetates
DE4025342A1 (de) * 1990-08-10 1992-02-13 Hoechst Ag In 17-stellung substituierte corticoid-17-alkylcarbonate, verfahren zu deren herstellung und diese enthaltende arzneimittel
WO1993025197A1 (en) * 1992-06-12 1993-12-23 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
US5622944A (en) * 1992-06-12 1997-04-22 Affymax Technologies N.V. Testosterone prodrugs for improved drug delivery
US5952319A (en) * 1997-11-26 1999-09-14 Research Triangle Institute Androgenic steroid compounds and a method of making and using the same
US20030069215A1 (en) * 2001-03-30 2003-04-10 The Government Of The United States Of America, Methods of making and using 7a,11b-dimethyl-17b-hydroxy-4-estren-3-one 17b-trans-4-n-butylcyclohexane carboxylate and 7a,11b-dimethyl-17b-hydroxyestr-4-en-3-one 17-undecanoate
CA2402524C (en) * 2000-03-31 2009-11-17 Richard P. Blye Methods of making and using 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxy-4-estren-3-one 17.beta.-trans-4-n-butylcyclohexane carboxylate and 7.alpha.,11.beta.-dimethyl-17.beta.-hydroxyestr-4-en-3-one 17-undecanoate
US20030134828A1 (en) * 2002-01-16 2003-07-17 Roberts William J. Composition and method for increasing in vivo androgen concentration
US20030134831A1 (en) * 2002-01-16 2003-07-17 Roberts William J Bioavailable prodrugs of androgenic steroids and related method
US6740646B2 (en) * 2002-01-16 2004-05-25 Biotest Laboratories, Llc Bioavailable prodrugs of androgenic steroids and related method

Also Published As

Publication number Publication date
EP1846434A1 (de) 2007-10-24
AU2006211907A1 (en) 2006-08-10
US20080167283A1 (en) 2008-07-10
JP2008530007A (ja) 2008-08-07
EP1846434B1 (de) 2009-03-25
US7820642B2 (en) 2010-10-26
AU2006211907B2 (en) 2011-09-08
JP5227593B2 (ja) 2013-07-03
DE602006005901D1 (de) 2009-05-07
CA2596884C (en) 2013-11-12
CA2596884A1 (en) 2006-08-10
WO2006083618A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
MX2021006034A (es) Agonistas de glp-ir y usos de los mismos.
CL2012002722A1 (es) Forma farmaceutica parenteral que libera un inhibidor de aromatasa tal como anastrozol y exemestano, y un gestageno tal como levonorgestrel y gestodeno; y su uso para el tratamiento simultaneo de endometriosis y para la anticoncepcion.
AR056806A1 (es) Moleculas quimericas de anticuerpo rankl- pth/ pthrp
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
WO2012127501A3 (en) Composition for improving endometrial thickness during ovarian stimulation
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
CL2014000428A1 (es) Metodo para el tratamiento de hepatitis c (hcv) que comprende administrar un compuesto de formula (i), (ii) o (iii) en combinacion con uno o mas agentes terapeuticos; composicion farmaceutica.
EP2421545A4 (de) Verfahren und vorrichtung zur synchronisierung der befruchtungszeit
BRPI0518483A2 (pt) composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
ECSP055629A (es) COMPOSICIÓN QUE CONTIENE UN ESTEROIDE 11ß-HALOGENADO ANDRÓGENO Y UN GESTÁGENO ASÍ COMO UN CONTRACEPTIVO MASCULINO SOBRE LA BASE DE ESTAS COMPOSICIONES
EA201400543A1 (ru) Способы и композиции для чрескожной доставки
MXPA06012980A (es) Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
BR112014000178A2 (pt) composições tópicas
MY177338A (en) Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance
HN2012000137A (es) Derivados de 17 - hidroxi - 17 - pentafluoroetil - estra - 4, 9(10) - dien - 11 - arilo, procedimientos para su preparacion y su uso para el tratamiento de enfermedades
AR063550A2 (es) Utilizacion de un derivado de pirazol para la preparcion de medicamentos utiles para la prevencion y eltratamiento de la displidemias y de las enefermedades asociadas a las dislipidemias y/o a la obesidad
PH12018501002A1 (en) Pheromone composition to stimulate reproduction in female suids and method of use
ATE426610T1 (de) Nandrolon-17ss-carbonate
EP2582371A4 (de) Verfahren zur behandlung oder verhinderung östrogen-vermittelter krankheiten
TN2009000358A1 (en) Pharmaceutical compositions comprising a calcilytic agent
WO2009076413A3 (en) Methods, devices and compositions for controlled drug delivery to injured myocardium
ATE528347T1 (de) Kautschukmischung
GT200600270A (es) Uso de moduladores no esteroides de receptores de progesterona
ZA201908404B (en) 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases
AR095834A1 (es) Forma de dosificación de un antagonista del receptor de progesterona, composición farmacéutica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties